CRNX Stock Analysis: Buy, Sell, or Hold?
CRNX - Crinetics Pharmaceuticals, Inc.
$49.94
-1.94 (-3.74%)
▼
HOLD
LOW Confidence
Last Updated: January 30, 2026
Earnings: Feb 26, 2026
26d
Get Alerted When CRNX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CRNX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CRNX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CRNX is currently trading at $49.94, which is considered fair relative to its 30-day fair value range of $48.26 to $54.90.
Technical Outlook: Technically, CRNX is in a strong uptrend. The price is currently testing key support at $49.31. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $84.50 (+62.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CRNX is in a strong uptrend. The price is currently testing key support at $49.31. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $84.50 (+62.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$48.26 -
$54.90
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
75.8%
Protect Your Profits
Holding CRNX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.7%)
- BULLISH: Trading 62.9% below Wall St target ($84.50)
- CAUTION: Recommendation downgraded due to -6.1% 5-day decline
Fair Price Analysis
30-Day Fair Range
$48.26 -
$54.90
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$3.36
(6.7%)
Support & Resistance Levels
Support Level
$49.31
Resistance Level
$56.99
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-10.02
Wall Street Target
$84.50
(+62.9%)
Revenue Growth (YoY)
158.4%
Last updated: January 30, 2026 4:15 PM ET
Data refreshes hourly during market hours. Next update: 5:15 PM
Data refreshes hourly during market hours. Next update: 5:15 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRNX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Dana Pizzuti
SELL
5000 shares
2025-10-01
Matthew K Fust
SELL
16000 shares
2025-09-26
Richard Scott Struthers
SELL
4000 shares
2025-09-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$66 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$90 | 59 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$108 | 56 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$35 | 51 HOLD |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$21 | 50 HOLD |
Advanced CRNX Option Strategies
Professional options setups generated by AI based on today's CRNX price and gamma walls.
